Lowering triglycerides to modify cardiovascular risk: will icosapent deliver?
Daniel J Scherer,1 Stephen J Nicholls2 1Cardiovascular Investigation Unit, Royal Adelaide Hospital, 2South Australian Health and Medical Research Institute, University of Adelaide, Adelaide, SA, Australia Abstract: Despite the clinical benefits of lowering levels of low-density lipoprotein choleste...
Main Authors: | Scherer DJ, Nicholls SJ |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2015-03-01
|
Series: | Vascular Health and Risk Management |
Online Access: | http://www.dovepress.com/lowering-triglycerides-to-modify-cardiovascular-risk-will-icosapent-de-peer-reviewed-article-VHRM |
Similar Items
-
Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia
by: M Aseem Basha
Published: (2019-01-01) -
Impact of Icosapent Ethyl on Cardiovascular Risk Reduction in Patients With Heart Failure in REDUCE‐IT
by: Senthil Selvaraj, et al.
Published: (2022-04-01) -
Cost-Effectiveness of Icosapent Ethyl (IPE) for the Reduction of the Risk of Ischemic Cardiovascular Events in Canada
by: Lachaine J, et al.
Published: (2023-04-01) -
Cardiovascular Benefits of Icosapent Ethyl in Patients With and Without Atrial Fibrillation in REDUCE‐IT
by: Brian Olshansky, et al.
Published: (2023-03-01) -
Icosapent ethyl for the treatment of severe hypertriglyceridemia
by: Fares H, et al.
Published: (2014-06-01)